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Abstract
Hospitals in France are encouraged to monitor antibiotic consumption (AbC) and it is known that this differs among hospitals. The aim
of the current study was to identify relevant and easily available adjustment criteria for the purpose of benchmarking. We analysed data
from 34 public non-teaching hospitals and 43 private hospitals located in south-western France and overseas departments using retro-
spective data from 2005. This study investigated the relationship between AbC expressed as deﬁned daily doses per 1000 patient-days
(DDD/1000 PDs) or per 100 admissions (DDD/100 admissions) and the number of venous central lines, the number of episodes of
bacteraemia and various hospital characteristics. The relationship was tested using multiple linear analyses. The median total AbC in
public hospitals was 395 DDD/1000 PDs (range, 196–737) and 341 DDD/100 admissions (range, 180–792). In private hospitals this was
422 DDD/1000 PDs (range, 113–717) and 212 DDD/100 admissions (range, 38–510). The best model for public hospitals included the
proportion of PDs in surgery, intensive care and medical wards and explained 84% of the variability in AbC expressed as DDD/1000
PDs. For private hospitals, the mean length of stay and the proportion of PDs in surgery and medical wards explained 68% of the vari-
ability in AbC expressed as DDD/100 admissions. Overall, this French experience shows that relevant adjustment criteria for the com-
parison among hospitals are easily available. It is important that each country establish its own model considering the intrinsic
peculiarities of the hospital system and taking into account both indicators (DDD/1000 PDs or DDD/100 admissions) to design the best
model.
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Introduction
The link between antibiotic consumption (AbC) and the
emergence of bacterial resistance has clearly been estab-
lished [1–3] and represents a major risk for human health
[4–6]. This problem is all the more worrying as few new
therapeutic antibiotic classes have been made available in the
past 20 years [7,8]. Those in the hospital setting are most
concerned by the emergence of resistance as its spread
results in increased length of stay, mortality and cost of
healthcare [5,9]. The monitoring of AbC and feedback to
prescribers is a prerequisite to drawing up and assessing
local, regional and national guidelines.
France is one of the European countries that consumes the
most antibiotics and also where the prevalence of resistance
among some bacteria is the highest [10,11]. In the context of
a national programme for nosocomial infection prevention,
French hospitals are encouraged to develop and implement
measures to rationalize and monitor AbC [12–14]. The refer-
ence method to express AbC exposure is the Anatomical
Therapeutic Chemical/DDD methodology that allows stan-
dardized comparisons among hospitals internationally. How-
ever, little is known about AbC in French hospitals [15–17].
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Benchmarking is a tool for improving results in an organi-
zation through systematic comparison with other organiza-
tions that are recognized as best in the ﬁeld [18,19], and has
allowed the improvement of AbC [20]. However, owing to
wide variations in AbC among hospitals [15,21], this method
requires adjustment criteria to provide valid comparators.
To clarify this issue, we used the experience of the hospitals
of south-western France, considering, in parallel, the number
of DDD per 1000 patient-days (DDD/1000 PDs) and DDD
per 100 admissions (DDD/100 admissions) to identify the
best model with relevant and easily available adjustment
criteria.
Methods
Study design and data source
An observational retrospective study was performed using a
postal questionnaire sent to the physician in charge of noso-
comial infection control in 90 non-teaching public and 122
private hospitals of south-western France. Hospitals that
answered positively could download an electronic question-
naire between 1 February and 31 May 2006 to collect the
2005 aggregate data of AbC.
Hospital characteristics
Each hospital was categorized according to its public or pri-
vate status. The types of wards were grouped according to
the French administrative deﬁnition: medical, surgical, inten-
sive care, obstetrics, medium- and long-term care, psychiatry,
paediatrics. Each hospital provided data regarding the num-
ber of beds and, for each ward group, the data regarding
activity were the number of PDs (stays > 24 h) spent in the
ward (the day of admission and discharge counted as one
PD) and the number of admissions.
The proportion of total hospital PDs for each ward
group was calculated by dividing the number of PDs of
each group by the total number of PDs of the hospital.
The mean length of stay was obtained by dividing the num-
ber of PDs by the number of admissions. Patient severity
criteria were the number of central venous lines (VCLs)
used and the number of bacteraemia episodes during the
entire year.
Hospital policy regarding AbC was obtained by question-
naire regarding resources and organization, covering the
existence of a local antibiotic committee, the existence of a
hospital antibiotic formulary, the existence of an infectious
disease consultant, feedback information on AbC, audit of anti-
biotic prescribing practices and computer connexion between
the microbiology laboratory and the pharmacy.
Antibiotic consumption
Data on AbC were collected by a standardized questionnaire
developed using EXCEL (Microsoft Corp., Redmond, WA,
USA). This form contained a program similar to the software
ABC calc developed by the Danish Statens Serum Institute
[22] available on the ESCMID website (www.escmid.org).
Pharmacies were requested to report the total number of
each formulation of each antibiotic dispensed that was auto-
matically converted into weight (grams), summed for the per-
iod of interest (1 calendar year) and divided by WHO-assigned
DDD (version 2006). Data were collected on all antibiotics for
systemic use (group J01 of the Anatomical Therapeutic Chemi-
cal, ATC, classiﬁcation system) [23]. Total consumption of
antibiotics was expressed as DDD/1000 PDs and as DDD/100
admissions. Emergency and out-patient AbC was excluded.
Statistical analysis
All statistical analyses were performed using SAS, version 9.1
(SAS Institute, Cary, NC, USA). The dependant variable (total
AbC expressed as DDD/1000 PDs and DDD/100 admissions)
and independent variables (hospital characteristics) were
described. Associations between continuous variables and
AbC were tested using univariate analyses with Spearman’s
correlation test (r). The best correlated independent variables
(r ‡ 0.30) were introduced into a multiple linear regression
model with a backward stepwise approach. The variable ‘Exis-
tence of an infectious disease consultant’ is a key element in
the control of AbC [24]. It was forced into multivariate models
to compare hospitals independently of their policies. We
retained variables that were statistically associated with AbC
with threshold p values of 0.10. An analysis of sensitivity was
performed with replacement of missing values by the average
of the variable to test model robustness.
Results
Hospital characteristics
Among the 212 hospitals contacted, 77 participated, of which
34 were public and 43 were private hospitals. Public hospi-
tals had a combined total of 12 265 beds (range 100–1131)
with a total of 3 688 533 PDs and 458 853 admissions. Pri-
vate hospitals were smaller, with a combined total of 5168
beds (range 28–380) and a total of 1 421 038 PDs and
320 950 admissions. This sample was representative of public
and private hospitals of south-western France regarding
length of stay and ward distribution (data not shown).
Activity and ward proﬁle were different between public and
private hospitals (Table 1). The median length of stay in private
hospitals was shorter than in public hospitals (4 vs. 8 days).
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Measures to improve AbC in public and private hospitals
were not different (Table 2) except for audit of antibiotic
prescribing practices (26% for public and 51% for private
hospitals, respectively; p <0.05).
Antibiotic consumption
The total AbC, expressed as DDD/1000 PDs, did not differ
signiﬁcantly according to the type of hospital (395 DDD/
1000 PDs for public vs. 422 DDD/1000 PDs for private
hospitals) whereas, when expressed as DDD/100 admis-
sions, there were signiﬁcant differences according to the
type of hospital (341 DDD/100 admissions for public vs.
212 DDD/100 admissions for private hospitals; p <0.001)
(Fig. 1).
Hospital characteristics associated with antibiotic consump-
tion
Results of univariate and multivariate analysis are presented
separately for the two types of hospital because characteris-
tics were very different. For public hospitals, the univariate
analysis showed that all the hospital characteristics investi-
TABLE 1. Hospital characteristics
Public hospitals Private hospitals
n*
25th
Percentile Median
75th
Percentile n*
25th
Percentile Median
75th
Percentile
Structure and activity criteria
Number of beds 34 182 311 485 43 63 99 152
Length of stay (days) 34 7 8 11 43 4 4 5
Proportion of patient days in surgery (%) 30 9 13 17 37 39 66 88
Proportion of patient days in intensive care (%) 33 0 2 3 41 0 0 0
Proportion of patient days in medical wards (%) 34 25 34 45 39 0 21 49
Proportion of patient days in obstetric wards (%) 34 2 4 6 41 0 0 9
Proportion of patient days in medium- and long-term
care and psychiatry wards (%)
32 32 42 62 43 0 0 0
Severity criteria
Number of venous central lines per 1000 patient days 23 1 3 3 27 2 2 5
Number of bacteraemia episodes per 1000 patient days. 23 1 2 2 22 1 1 3
*Number of hospitals for which data were available.
TABLE 2. Policies to improve antibiotic use, positive
responses
Public
hospital,
% (n = 34)
Private
hospital,
% (n = 43)
Existence of a local antibiotics committee 91 78
Existence of a hospital antibiotic formulary 91 78
Existence of an infectious diseases consultant 61 49
Feedback information on antibiotic consumption 85 84
Audit of antibiotic prescribing practice 26* 51*
Computer connexion between the microbiology
laboratory and the pharmacy
24 7
p <0.05, Fisher’s exact test
FIG. 1. Distribution of total antibiotic con-
sumption in public and private hospitals,
expressed as deﬁned daily doses (DDD)/1000 p-
atient-days and 100 admissions. The box
stretches from the lower hinge (the 25th
percentile) to the upper hinge (the 75th percen-
tile). The median is shown as a line across the b-
ox. Therefore, a quarter of the distribution is
between this line and the top of the box. The line
above the upper hinge is the 90th percentile and
the line below the lower hinge is the 10th per-
centile. Filled circles represent hospitals which
have a total consumption superior at the 90th p-
ercentile or inferior at the 10th percentile.
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gated were signiﬁcantly correlated with AbC when
expressed as DDD per 1000 PDs, except the total number
of beds.
Total AbC was negatively correlated with the proportion
of PDs in medium- and long-term care and psychiatry wards
as well as length of stay. Conversely, total AbC was corre-
lated positively and most strongly with the proportion of
PDs in medical wards and VCLs (Table 3).
When total AbC was expressed as DDD/100 admissions,
it was associated with the length of stay and the number of
beds, but these associations were weaker and thus the indi-
cator expressed as DDD/1000 PDs was the most relevant
for multivariate analysis. In the resulting models, it was signif-
icantly associated with the proportion of PDs in surgery,
intensive care and medical wards (Table 4). These character-
istics explained 84% of the variation in AbC. A difference of
1% of PDs in intensive care between two public hospitals,
adjusted with respect to the other variables, led to an
increase of 29.3 DDD/1000 PDs (90% conﬁdence intervals
(CI), 14.9; 43.6). Few hospitals had an AbC predicted by this
model that was far from the actual AbC (Fig. 2).
For private hospitals, the AbC expressed as DDD/1000
PDs was only weakly associated with hospital characteristics,
but when expressed as DDD/100 admissions, the association
was stronger. Total AbC was positively correlated with the
length of stay (r = 0.81; p <0.01), the proportion of PDs in
medical wards (r = 0.49; p <0.01) and the proportion of PDs
in surgery (r = 0.48; p <0.01) (Table 3). The AbC expressed
as DDD/100 admissions allowed a better explanation of the
variability in AbC in private hospitals according to multivari-
ate analysis.
TABLE 3. Relationship between
total antibiotic consumption
(deﬁned daily doses (DDD)/1000
patient-days (PDs) and DDD/100
admissions) and hospital character-
istics
Total antibiotic consumption
Public hospitals Private hospitals
DDD/1000
PDs
DDD/100
admissions
DDD/1000
PDs
DDD/100
admissions
Number of beds 0.06 )0.43* 0.31* 0.26
Length of stay (days) )0.72* 0.52* 0.25 0.81*
Proportion of patient days in surgery 0.51* )0.33 )0.20 )0.48*
Proportion of patient days in intensive care 0.58* )0.20 0.31* 0.19
Proportion of patient days in medical wards 0.78* )0.04 0.31 0.49*
Proportion of patient days in obstetric wards 0.62* )0.22 0.08 0.10
Proportion of patient days in medium- and
long-term care and psychiatry wards
)0.86* 0.20 )0.19 0.05
Number of venous central lines
(per 1000 patient days or 100 admissions)
0.74* 0.02 0.48 0.41*
Number of bacteriaemia episodes
(per 1000 patient days or 100 admissions)
0.59* 0.03 0.28 0.55*
*p <0.05, Spearman’s coefﬁcient.
TABLE 4. Multivariate model for the total consumption of
antibiotics in the public hospitals (Adjusted R2 = 0.84)
Public hospital
Total consumption
(DDD per 1000 patient-days)
Coefﬁcient 90% CI p value
Constant 135.3 (85.7; 184.9) <0.01
Proportion of patient days in intensive care 29.3 (14.9; 43.6) <0.01
Proportion of patient days in surgery 5.1 (2.1; 8.1) <0.01
Proportion of patient days in medical wards 4.7 (3.2; 6.2) <0.01
Existence of infectious diseases consultant 18.6 ()17.5; 54.7) NS
FIG. 2. Multivariate model of antibiotic consumption in the public
hospitals (actual vs. predicted). The model used to calculate the pre-
dicted consumption was as follows: predicted antibacterial consump-
tion expressed as deﬁned daily doses (DDD)/1000 patient-days
(PDs) = 135.3 + 28.3 (proportion of PDs in intensive care) + 5.1
(proportion of PDs in surgery) + 4.7 (proportion of PDs in medical
ward) + 18.6 (existence of infectious diseases consultant). Filled cir-
cles represent hospitals. The horizontal line indicates the median
value of actual antibiotic consumption. The continuous line and the
two discontinuous lines represent the predicted antibiotic consump-
tion and 90% prediction intervals, respectively.
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The length of stay, and to a lesser extent the proportion
of PDs, in the medical and surgical wards were predictors of
the variation in AbC (adjusted R2 = 0.67) (Table 5). Between
two hospitals that had the same structure of wards but with
lengths of stay that varied by one day, AbC differed by 55.0
DDD per 100 AD (90% CI, 42.0; 68.0). There was a statisti-
cally signiﬁcant difference between predicted and recorded
AbC for several hospitals (Fig. 3). No measure undertaken
to improve AbC was signiﬁcantly associated with AbC.
Discussion
For valid benchmarking techniques, adjustment criteria must
be deﬁned according to the context and objective of the
project. In the study described herein, we report the French
experience in order to show the identiﬁed adjustment
criteria for AbC on one hand and, on the other hand, the
importance of considering, in parallel, the number of DDD/
1000 PDs and 100 admissions to explain the variation in
AbC. This may help other countries to construct their own
models for comparison among hospitals, as the adjustment
criteria considered are easily available and the models may
be reﬁned if both indicators are taken into consideration.
Herein, separate models for private and public hospitals
were constructed. This highlights the importance of taking
into account the characteristics of a given hospital care sys-
tem, which can change from one country to another, in
order to identify relevant adjustment criteria. To give an
example, most hospitals in western Europe now concentrate
on acute care, whereas most hospitals in eastern Europe and
some parts of southern Europe continue to provide social-
as well as acute-care services [25]. Thus, it is unlikely that
any model constructed to explain the variation of AbC in
one country would be applicable to a second country with-
out some change.
Our experience has shown that the activity of public
hospitals, expressed as the proportion of PDs in surgery,
intensive care and medical wards, was found to be the
most informative adjustment criterion. This alone could
therefore be used as a surrogate marker for case mix
adjustment in order to interpret differences in AbC for
benchmarking (expressed in DDD/1000 PDs). Similarly, as
for private hospitals, we found that the proportion of PDs
in medical wards and surgery, but also the length of stay,
provided the best ﬁt for AbC, but in this case expressed
as DDD/100 admissions. Interestingly, and seemingly in
contradiction to previous studies [21,26], in the ﬁnal multi-
variate models, neither the number of VCLs nor the cases
of bacteraemia were retained; probably because these
studies were conducted at the ward level. With the high
proportion of variability identiﬁed using the models, it
does not seem worthwhile to further investigate other
severity criteria concerning patients. However, the con-
struction of similar models in other countries could
require the consideration of severity criteria.
The present study demonstrates the beneﬁt of considering
both the number of DDD/1000 PDs and per 100 admissions
to establish the best model, although the most often pub-
lished variable is DDD/1000 PDs. The ﬁnding that antibiotic
comsumption expressed in DDD/1000 PDs is more relevant
to explain the variation in the consumption in the public hos-
pitals, whereas the indicator for 100 admissions is more
interesting in the context of private hospitals, does not mean
that a country has to have the same system of hospital care
TABLE 5. Multivariate model for the total consumption of
antibiotics in the private hospitals (Adjusted R2 = 0.67)
Private hospital
Total consumption
(DDD per 100 admissions)
Coefﬁcient 90% CI p value
Constant )200.6 ()361.4; 39.8) 0.04
Length of stay (days) 55.0 (42.0; 68.0) <0.01
Proportion of patient days in surgery 1.7 (0.3; 3.1) 0.06
Proportion of patient days in medical wards 1.6 (0.2; 3.0) 0.06
Existence of infectious diseases consultant 1.7 ()35.4; 38.8) NS
FIG. 3. Multivariate model of antibiotic consumption in the public
hospitals (actual vs. predicted). The model used to calculate the pre-
dicted consumption was as follows: predicted antibiotic consumption
expressed in deﬁned daily doses (DDD)/100 admis-
sions = )200.6 + 55.0 (length of stay (days)) + 1.7 (proportion of
patient-days (PDs) in surgery) + 1.6 (proportion of PDs in medical
ward) + 18.6 (existence of infectious diseases consultant). Filled cir-
cles represent hospitals. The horizontal line indicates the median
value of actual antibiotic consumption. The continuous line and the
two discontinuous lines represent the predicted antibiotic consump-
tion and 90% prediction intervals, respectively.
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as that in France to consider either indicator. The relevance
of this unit of measurment has already been shown in fol-
low-up trends in longitudinal studies [27,28].
Most of the few studies regarding factors associated with
hospital AbC [26,29–35], published for the purpose of com-
parison, differ from the present study with respect to size
and type of sample investigated, limiting comparability.
To our knowledge, only one recently published study con-
sidered a sample similar to that investigated here [21]. The
authors, MacDougall et al., described a model that incorpo-
rated the factors of number of beds, number of intensive
care unit days per 1000 PDs, number of surgeries per 1000
discharges, and number of cases of pneumonia, bacteraemia
and urinary tract infection. This model explained 31% of the
variability in the volume of antibiotics consumed in a non-
random sample of 130 medical–surgical hospitals in the USA.
In the current study, we also used a non-random sample of
hospitals, but this was found to be representative of the hos-
pitals in south-western France regarding length of stay and
ward distribution. Moreover, certain criteria used by Mac-
Dougall et al. are not routinely available in the absence of
computerized patient ﬁles. Such systems are still rare in Eur-
ope and probably even more so in others parts of the world.
In the current study, although patient severity was investi-
gated, we found that more easily obtainable indicators, such
as hospital characteristics, can be used for adjustment, which
represents a considerable advantage.
A potential limitation of the study can be found in the
use of DDD as the unit of AbC, as the methodological
concept of ‘days of therapy’ proposed by Polk et al. [36]
represents an attractive alternative. Indeed, these authors
discuss the limitation of the term DDD and report discrep-
ancies between DDD and the number of days of therapy.
However, days of therapy can only be calculated in institu-
tions that have access to pharmacy data at the patient level
which, in the current study, could not be provided by most
of the hospitals. More importantly, DDD is the reference
for the purpose of standardized comparisons at national
and international levels [37]. It is thus the best adapted for
the purpose of deﬁning adjustment criteria. Additionally, in
this study, ward distribution could be calculated using the
number of beds, which is a variable easier to collect than
the number of PDs. However, the quality of these mea-
sures is not equal because the number of beds does not
indicate whether the bed is occupied, and the bed occu-
pancy rate can vary among hospitals and bias the measure-
ment. Such problems can be avoided using the measure of
PDs. Finally, aggregate data at the hospital level were used
and models may be reﬁned by identifying criteria at the
ward level as reported elsewhere [26,29]. However, the
survey of AbC at the hospital level is the ﬁrst step in iden-
tifying an AbC misuse. Using this type of model, a hospital
can quickly identify a variation in AbC.
To give an example, a hospital which would have a pre-
dicted AbC very different from the actual consumption
should investigate the reason for this discrepancy. The mod-
els could allow the identiﬁcation of outlier hospitals and help
them to diagnose a problem in their AbC.
In conclusion, the present study has shown that easily
available adjustment criteria can be relevant for comparison
among hospitals in France, which may help other countries
to establish their own, most adequate models if the intrinsic
peculiarities of their hospital systems are considered and
both indicators (DDD/1000 PDs or DDD/100 admissions)
are investigated.
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